Table 2.

Predicted canonical pathways affected in GOT1 tumors after ¹⁷⁷Lu-octreotate therapy with priming

	Ingenuity Canonical Pathways	p	Targets from transcriptional data
1 day
	Systemic lupus erythematosus signaling	1.3 × 10−4	↓RNU1-3, ↓RNU1-5, ↓RNU1A3
►	PI3K/AKT signaling	3.4 × 10−3	↑PPP2R2B, ↑CDKN1A, ↑GDF15
	Taurine biosynthesis	5.0 × 10−3	↓CDO1
►	Role of CHK proteins in cell cycle checkpoint control	8.3 × 10−3	↑PPP2R2B, ↑CDKN1A
	L-cysteine degradation	1.0 × 10−2	↓CDO1
3 days
	p53 signaling	3.2 × 10−5	↑GADD45A, ↑TNFRSF10B, ↑CDKN1A, ↑TIGAR, ↑BAX
	GADD45 signaling	3.2 × 10−5	↑CCND3, ↑GADD45A, ↑CDKN1A
►	Unfolded protein response	7.1 × 10−4	↑DDIT3, ↓INSIG1, ↑HSPH1
	Cholesterol biosynthesis	8.1 × 10−4	↓FDFT1, ↓MSMO1
►	Death receptor signaling	3.6 × 10−2	↑ACTA2, ↑TNFRSF10B
7 days
	Systemic lupus erythematosus signaling	1.3 × 10−4	↓RNU1-3, ↓RNU1-5, ↓RNU4-2, ↓RNU4-1
	LXR/RXR activation	1.3 × 10−3	↓FDFT1, ↑APOE, ↓LDLR, ↑ABCA1
►	Epoxysqualene biosynthesis	7.8 × 10−3	↓FDFT1
►	p53 signaling	9.3 × 10−3	↑TNFRSF10B, ↑CDKN1A, ↑SERPINE2
►	Serotonin and melatonin biosynthesis	2.0 × 10−2	↑TPH1
41 days
►	Role of Oct4 in mammalian embryonic stem cell pluripotency	1.6 × 10−3	↓SOX2, ↓NR2F2
►	Lactose degradation	5.3 × 10−3	↑GBA3
►	CDK5 signaling	7.1 × 10−3	↓EGR1, ↑PPP2R2C
	Embryonic stem cell differentiation into cardiac lineages	1.3 × 10−2	↓SOX2
►	Wnt/β-catenin signaling	2.0 × 10−2	↓SOX2, ↑PPP2R2C

Significantly affected canonical pathways identified with IPA (Fisher’s exact test, p < 0.05), ranked according to the lowest p value, for each time point. Up and down arrows indicate upregulated and downregulated genes in tumor samples from treated animals compared with controls, respectively. ► indicates the pathway was not affected in animals treated with 15 MBq single administration of ¹⁷⁷Lu-octreotate (from GEO accession GSE80024)